Kiso Ji Biotechnology is a leading next-generation antibody company focused on discovering and developing highly differentiated antibody therapeutics for challenging targets in oncology and other diseases. Their proprietary antibody platform utilizes multi-species single domain antibody transgenic mice and AI-enabled antibody fingerprinting technology, allowing for unprecedented control over antibody sampling. The company has developed a preclinical pipeline that includes a novel TROP2 antibody, KJ-103, which is currently in IND-enabling studies, showcasing their innovative approach to antibody drug development and positioning them strongly in the biotechnology market.
Something looks off?On-site & Remote